VIP (Vasoactive Intestinal Peptide) vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →Side-by-Side Comparison
| Aspect | VIP (Vasoactive Intestinal Peptide) | Semaglutide |
|---|---|---|
| Mechanism | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. |
| Typical Dosage | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. |
| Administration | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. |
| Side Effects | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. |
| Best For |
What They Have in Common
Both VIP (Vasoactive Intestinal Peptide) and Semaglutide are commonly used for:
Key Differences
Unique to VIP (Vasoactive Intestinal Peptide):
Unique to Semaglutide:
Detailed Analysis
Both Semaglutide and VIP (Vasoactive Intestinal Peptide) are commonly used for Gut Health.
Which Should You Choose?
Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.